GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocure Technology Inc (XCNQ:CURE) » Definitions » Cyclically Adjusted Price-to-FCF

Biocure Technology (XCNQ:CURE) Cyclically Adjusted Price-to-FCF : (As of Jun. 07, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Biocure Technology Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Biocure Technology Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Biocure Technology's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocure Technology Cyclically Adjusted Price-to-FCF Chart

Biocure Technology Annual Data
Trend Mar15 Mar16 Mar17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biocure Technology Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biocure Technology's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Biocure Technology's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocure Technology's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocure Technology's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biocure Technology's Cyclically Adjusted Price-to-FCF falls into.


;
;

Biocure Technology Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Biocure Technology's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Biocure Technology's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.001/127.3637*127.3637
=-0.001

Current CPI (Dec. 2024) = 127.3637.

Biocure Technology Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 -0.001 99.789 -0.001
201506 -0.002 100.500 -0.003
201509 -0.002 100.421 -0.003
201512 -0.002 99.947 -0.003
201603 0.000 101.054 0.000
201606 -0.002 102.002 -0.002
201609 -0.003 101.765 -0.004
201612 0.000 101.449 0.000
201703 0.000 102.634 0.000
201706 -0.002 103.029 -0.002
201709 -0.003 103.345 -0.004
201712 -0.056 103.345 -0.069
201803 -0.097 105.004 -0.118
201806 -0.105 105.557 -0.127
201809 -0.044 105.636 -0.053
201812 -0.086 105.399 -0.104
201903 -0.101 106.979 -0.120
201906 -0.063 107.690 -0.075
201909 -0.080 107.611 -0.095
201912 -0.102 107.769 -0.121
202003 -0.039 107.927 -0.046
202006 -0.030 108.401 -0.035
202009 -0.017 108.164 -0.020
202012 -0.035 108.559 -0.041
202103 -0.015 110.298 -0.017
202106 -0.010 111.720 -0.011
202109 -0.058 112.905 -0.065
202112 -0.011 113.774 -0.012
202203 -0.032 117.646 -0.035
202206 -0.014 120.806 -0.015
202209 -0.007 120.648 -0.007
202212 -0.015 120.964 -0.016
202303 -0.020 122.702 -0.021
202306 -0.001 124.203 -0.001
202309 -0.001 125.230 -0.001
202312 0.006 125.072 0.006
202403 0.000 126.258 0.000
202406 0.003 127.522 0.003
202409 0.000 127.285 0.000
202412 -0.001 127.364 -0.001

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biocure Technology  (XCNQ:CURE) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Biocure Technology Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Biocure Technology's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocure Technology Business Description

Traded in Other Exchanges
Address
1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 2E9
Biocure Technology Inc is a biopharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It is Developing Biosimilars and CAR-T Cell pharmaceuticals. Its products are CAR-T Cell Therapy, Interferon Beta, Ranibizumab, and PEG-Filgrastim.
Executives
Konstantin Lichtenwald Director, Senior Officer

Biocure Technology Headlines